Impact of a Clinical Pathway for Pelvic Fragility Fractures (NCT06054165) | Clinical Trial Compass
RecruitingNot Applicable
Impact of a Clinical Pathway for Pelvic Fragility Fractures
Netherlands393 participantsStarted 2024-01-21
Plain-language summary
Patients with pelvic fragility fractures suffer from high morbidity and mortality rates. Despite the high incidence of these injuries, there is currently no regional or nationwide treatment protocol which results in a wide variety of clinical practice. New insights in treatment strategies, such as early diagnosis and minimal invasive operative treatment of these fragile patient population, has led to the development of several clinical pathways in recent literature. The aim of this study is to implement an evidence and experience-based treatment clinical pathway to improve the outcomes in this fragile patient population that currently has multifactorial risks for poor outcome.
Who can participate
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pelvic fragility fracture caused by low energetic trauma
* Patients presented at the emergency room or out-patient clinic of a participating hospital
Exclusion Criteria:
* Patients with high suspicion of a pelvic fracture due to a malignant tumor
* Patients who are unable to follow instructions due to severe cognitive decline (for example due to dementia or Alzheimer's disease)
* Patients who pre-trauma received palliative or terminal care
* Patients who pre-trauma were wheelchair bound or bedridden
* Patients who suffer from complications from previous pelvic ring fixation
* Patients with insufficient comprehension of the Dutch language to be able to carry out the physiotherapy instructions for early mobilization
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Mobility, using the Parker mobility score (PMS)
Timeframe: Change from baseline PMS at 2 weeks, 3 months, 6 months, and 1 year
Trial details
NCT IDNCT06054165
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)